Originally published by our sister publication Specialty Pharmacy Continuum
By Fran Kritz
On April 15, President Trump issued an executive order aimed at lowering prescription drug prices that requires the FDA commissioner to issue a report within 180 days “providing administrative and legislative recommendations to accelerate approval of generics, biosimilars, combination products, and second-in-class brand name medications.”
In a fact sheet the White House summarized efforts to